1. The problems of many, small, scattered and disorderly pharmaceutical enterprises are prominent, and there is a lack of large leading enterprises.

　　There are 3613 pharmaceutical enterprises in China, including 423 large enterprises, accounting for only 11.7% of the total. Most enterprises are not highly specialized and lack their own brands and characteristic varieties. Most enterprises not only have small scale, poor production conditions, backward technology, outdated equipment and low management level, but also have scattered layout. The production concentration of enterprises is far lower than that of advanced countries. In 2000, the production concentration of 6D enterprises with the largest sales in China's pharmaceutical industry was 35.7%, while the sales of the world's top 20 pharmaceutical enterprises accounted for about 60% of the world drug market share.

　　2. The enterprise centered technological innovation system has not yet been formed.

　　The foundation of new drug innovation is weak, the mechanism of pharmaceutical technology innovation and rapid industrialization of scientific and technological achievements has not been fully formed, the investment in pharmaceutical science and technology is insufficient, there is a lack of new products with China's independent intellectual property rights, the product renewal is slow and the duplication is serious. 97% of chemical APIs are "Imitation products. More old products and less new products; More low-grade and low value-added products, less high-tech and high value-added products; There are many varieties of repeated production and few exclusive brands. Some products such as gentamicin, paracetamol, vitamin B1 and metronidazole are produced by dozens or even hundreds of enterprises. Even for new products, the phenomenon of repeated production is also very serious. For example, 34 enterprises produce levofloxacin preparations and 35 enterprises produce clarithromycin preparations.

　　The pace of applying high and new technology to transform traditional industries is slow. Most old products have low technical and economic indicators, backward technology, high cost and lack international competitiveness.

　　3. The pharmaceutical circulation system is not perfect.

　　After the three-level wholesale pattern formed under the planned economic system was basically broken, a new and effective pharmaceutical circulation system has not been fully formed, and the illegal drug market has been banned repeatedly. Coupled with the low-level repeated construction in the production field for many years, most varieties are seriously oversupplied, the circulation order is chaotic, and the task of governance is arduous. However, leading pharmaceutical circulation enterprises such as Kyushu Tong, Sinopharm holdings and China resources are now acquiring commercial companies on a large scale to change the current situation of the pharmaceutical market.

　　4. The quality and performance of medical devices are poor.

　　Most of the medical devices that can be produced in China are conventional medium and low-grade products with low added value, while most of the high, precision and sharp medical devices and new practical medical devices needed in clinic need to be imported. The upgrading of conventional medical devices is slow, the scientific and technological content is low, the product quality can not meet the requirements of high quality of medical and health, the product repair rate and shutdown rate are higher than those of similar foreign products, and the reliability of the product is unstable.

　　5. The type of preparation does not match the type of API.

　　China is already a large producer of API in the world, but the research on the technical development of pharmaceutical preparations is not enough, the preparation level is low, and the quality of most preparation products is not high, so it is difficult to enter the international market: on average, one API in China can only be made into three preparations, while one API abroad can be made into more than ten or even dozens of preparations; The preparation technology is backward and the quality stability of preparation products is not high.

　　6. The import and export structure of pharmaceutical products is unreasonable.

　　China still does not get rid of the traditional import and export mode of chemical raw materials, conventional surgical instruments, sanitary materials and traditional Chinese medicine with low added value and heavy pollution, while the import and export mode of expensive preparations and large and high-grade medical equipment, and the export proportion of high-tech products is low.

　　The international market development is not enough, the information channel is not smooth, and the response to the international market information is slow. In particular, there is a lack of awareness and mechanism to jointly explore the international market.